



HOUSE COMMITTEE ON APPROPRIATIONS

FISCAL NOTE

HOUSE BILL NO. 1295

PRINTERS NO. 2277

PRIME SPONSOR: DiGirolamo

COST / (SAVINGS)

FUND	FY 2015/16	FY 2016/17
General Fund	\$0	See Fiscal Impact

SUMMARY: House Bill 1295, Printer's Number 2277, adds buprenorphine to the Methadone Death and Incident Review Act and renames it the Methadone and Buprenorphine Death and Incident Review Act. This legislation is effective in 60 days.

ANALYSIS: The Methadone Death and Incident Review Act created the Methadone Death and Incident Review Team (MDAIR Team) in the Department of Drug and Alcohol Programs (DDAP) in 2012 to review and examine the circumstances surrounding methadone-related deaths and incidents for the purpose of promoting safety, reducing deaths/incidents and improving treatment practices. This legislation expands the review to include buprenorphine-related deaths and incidents. Buprenorphine, also known by the brand names Suboxone and Subutex, is an opioid drug used in medication assisted treatment for opioid dependence. The name of the review team is updated to the Methadone and Buprenorphine Death and Incident Review Team.

FISCAL IMPACT: According to the Methadone Death and Incident Review 2014 Annual Report, the number of case referrals increased 63% in 2014, from 146 referrals in 2013 to 238 referrals in 2014. In addition, the 2014 Annual Report indicated that 28 cases from 2013 and 187 cases from 2014 were still being investigated and would then be presented to the MDAIR Team. The Department of Drug and Alcohol Programs anticipates that two additional staff will be needed to accommodate the buprenorphine-related case referrals. The estimated annual cost for two additional Drug and Alcohol program staff to investigate buprenorphine-related deaths and incidents is \$216,000.

PREPARED BY: Ann Bertolino
House Appropriations Committee (R)

DATE May 18, 2016

Estimates are calculated using the best information available. Actual costs and revenue impact incurred may vary from estimates.